X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The CEP-Program is based on pre-clinical and clinical findings of Veyonda enhancing the anti-cancer effect of a number of standard chemotherapeutic agents. Receiving the ODD will speed up the Company’s commercial development plan for the important US market.
Lead Product(s): Idronoxil,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Veyonda
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Veyonda ® is the first drug candidate in the Company's pipeline, which is currently in a Phase 2 clinical trial. Veyonda (idronoxil) is a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with a moderate form of COVID-19.
Lead Product(s): Idronoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2021
Details:
This result validates the survival benefit of the same combination seen in a recently completed Phase I/II trial of Veyonda in men with end-stage metastatic castrate-resistant prostate cancer (mCRPC).
Lead Product(s): Idronoxil,Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area: Oncology Product Name: Veyonda
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2021
Details:
IND granted by FDA on evidence that Veyonda may increase generally poor response rates of sarcoma cancers to chemotherapy. The Company has a patent application currently under examination that relates to use of idronoxil in combination with various chemotherapy drugs.
Lead Product(s): Idronoxil
Therapeutic Area: Oncology Product Name: Veyonda
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2021
Details:
In a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease.
Lead Product(s): Idronoxil
Therapeutic Area: Immunology Product Name: Veyonda
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021
Details:
The patent application is aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses.
Lead Product(s): Idronoxil
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Veyonda
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2021
Details:
Part 1 of the NOXCOVID-1 trial involved 26 patients and was a dose-escalation arm testing the safety of increasing (400, 600, 800, 1200, 1800 mg) daily Veyonda dosages.
Lead Product(s): Idronoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
Details:
The experimental anti-cancer drug, Veyonda®, joins a number of approved and experimental drugs with an anti-inflammatory action being tested globally for their ability to block rapid progression of COVID-19 disease from moderate to severe level.
Lead Product(s): Idronoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The study revealed that in late-stage prostate cancer patients who have exhausted all standard treatment options, a combination of 177Lu-PSMA-617 and Veyonda® is both safe and delivered promising efficacy outcomes, among them a median overall survival of 17.1 months.
Lead Product(s): Idronoxil,Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area: Oncology Product Name: Veyonda
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
This action is designed to provide important safety data and proof-of-principle of using Veyonda®, as a potential treatment of the cytokine storm and septic shock that have emerged as major causes of morbidities and death in COVID-19 patients.
Lead Product(s): Idronoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
The posters addressed how NOX66 may improve treatment responses in men with mCRPC and also its contribution to restoring sensitivity to apoptosis and potentially modulating the immune microenvironment of nasopharyngeal carcinoma (NPC).
Lead Product(s): Idronoxil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
Noxopharm proposes to evaluate idronoxil use in patients at risk of developing acute respiratory distress syndrome (ARDS) and multi-organ failure associated with COVID-19 infection.
Lead Product(s): Idronoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
The alliance formalises a program under which Noxopharm has been making Veyonda® available through GenesisCare as an adjunctive therapy with 177Lu-PSMA therapy for mCRPC patientsin Australia.
Lead Product(s): Idronoxil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: GenesisCare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
